| Generic name | Rituximab and hyaluronidase human |
| Pronunciation | ri-TUK-si-mab & hye-al-yoor-ON-i-dase |
| Brand name(s), other common name(s) | Rituxan HycelaTM |
| Drug type | Monoclonal antibody |
| How the drug is given | Subcutaneous (SC) injection |
Indications and Usage
Rituximab and hyaluronidase human is a combination of rituximab, a CD20-directed cytolytic antibody, and hyaluronidase human, an endoglycosidase, indicated for the treatment of adult patients with:
- Follicular Lymphoma (FL)
- Relapsed or refractory, follicular lymphoma as a single agent
- Previously untreated follicular lymphoma in combination with first line chemotherapy and, in patients achieving a complete or partial response to rituximab in combination with chemotherapy, as single agent maintenance therapy
- Non-progressing (including stable disease), follicular lymphoma as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy
- Diffuse Large B-cell Lymphoma (DLBCL)
- Previously untreated diffuse large B-cell lymphoma in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens
- Chronic Lymphocytic Leukemia (CLL)
- Previously untreated and previously treated CLL in combination with fludarabine and cyclophosphamide (FC)
Limitations of Use:
- Initiate treatment with RITUXAN HYCELA only after patients have received at least one full dose of a rituximab product by intravenous infusion.
Side effects needing medical attention
Most common adverse reactions are:
- FL: infections, neutropenia, nausea, constipation, cough, and fatigue
- DLBCL: infections, neutropenia, hair loss, nausea, and anemia
- CLL: infections, neutropenia, nausea, thrombocytopenia, fever, vomiting, and injection site erythema
For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.